ResApp Health Ltd (ASX: RAP) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


ResApp Health Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $167.64 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 859.70 million
Earnings per share -0.009
Dividend per share N/A
Year To Date Return 200.00%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

ResApp Health Ltd (ASX: RAP)
Latest News

rising medical asx share price represented by woman stretching happily in bed
Mergers & Acquisitions

ResApp share price explodes 50% on new Pfizer deal

The ResApp share price is launching upwards after Pfizer upped its takeover bid for the company.

Read more »

A man looks down with fright as he falls towards the ground.
Share Fallers

Why Bowen Coking Coal, Lake Resources, Premier, and ResApp shares are tumbling lower

These ASX shares are having a tough day...

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Mergers & Acquisitions

Why is the ResApp share price crashing 29% today?

ResApp shares have been hammered on Tuesday...

Read more »

a medical person in full protective clothing holds a tray of Covid-19 vaccinations amid a haze caused by cold and ice.
Healthcare Shares

ResApp share price frozen as $180m Pfizer takeover bid hangs in the balance

The value of Pfizer's takeover bid may soon come to light.

Read more »

four excited doctors with their hands in the air
Share Market News

This ASX share is defying the odds to crack new 52-week highs

This health share is certainly kicking goals today.

Read more »

Share Gainers

Why Computershare, Lithium Plus, Lynas, and ResApp shares are pushing higher

These ASX shares are pushing higher today...

Read more »

A young man wearing glasses and a denim shirt sits at his desk and raises his fists and screams with delight as he watches the ResApp share price go 50% higher today
Mergers & Acquisitions

Here’s why the ResApp share price is rocketing 50% today

ResApp shares are breaking out today following an improved acquisition offer from Pfizer Australia.

Read more »

Green arrow going up on stock market chart, symbolising a rising share price.
Share Gainers

Why Australian Clinical Labs, Lake Resources, PolyNovo, and ResApp are rising

These ASX shares are pushing higher despite the market selloff...

Read more »

RAP ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About ResApp Health Ltd

ResApp Health Ltd is engaged in development and commercialization of the ResApp technology for the purpose of providing health care solutions for respiratory disease. The company's solutions are designed to be easily integrated into existing telehealth solutions and it is working on apps to provide respiratory disease diagnosis and management directly to consumers and healthcare providers. Its products are for Acute Disease Diagnosis; for Chronic Disease Management; and for Sleep Apnoea.

RAP Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
11 Aug 2022 $0.20 $0.00 0.00% 2,320,298 $0.19 $0.20 $0.19
10 Aug 2022 $0.20 $0.01 5.26% 3,103,696 $0.20 $0.20 $0.19
09 Aug 2022 $0.19 $-0.01 -5.13% 2,874,699 $0.19 $0.20 $0.19
08 Aug 2022 $0.20 $0.01 5.26% 10,378,248 $0.20 $0.20 $0.19
05 Aug 2022 $0.19 $0.00 0.00% 9,031,756 $0.19 $0.20 $0.19
04 Aug 2022 $0.19 $0.01 5.56% 10,945,897 $0.18 $0.19 $0.18
03 Aug 2022 $0.18 $0.06 50.00% 30,226,656 $0.13 $0.19 $0.12
02 Aug 2022 $0.12 $0.00 0.00% 489,431 $0.12 $0.12 $0.12
01 Aug 2022 $0.12 $0.00 0.00% 5,778,203 $0.12 $0.12 $0.12
29 Jul 2022 $0.12 $0.00 0.00% 290,609 $0.12 $0.12 $0.12
28 Jul 2022 $0.12 $0.00 0.00% 3,792,081 $0.12 $0.12 $0.12
27 Jul 2022 $0.12 $0.00 0.00% 3,317,354 $0.12 $0.12 $0.11
26 Jul 2022 $0.12 $0.01 9.09% 7,748,489 $0.11 $0.12 $0.11
25 Jul 2022 $0.11 $-0.01 -8.33% 5,488,405 $0.12 $0.12 $0.11
22 Jul 2022 $0.12 $-0.01 -8.00% 7,897,692 $0.13 $0.13 $0.12
21 Jul 2022 $0.13 $-0.01 -7.41% 6,234,058 $0.14 $0.14 $0.13
20 Jul 2022 $0.14 $-0.01 -7.14% 9,849,926 $0.14 $0.14 $0.13
19 Jul 2022 $0.14 $0.01 7.41% 890,390 $0.14 $0.14 $0.14
18 Jul 2022 $0.14 $0.00 0.00% 14,163,180 $0.14 $0.14 $0.14
15 Jul 2022 $0.14 $0.00 0.00% 545,088 $0.14 $0.14 $0.13
14 Jul 2022 $0.13 $0.00 0.00% 2,195,950 $0.14 $0.14 $0.13
13 Jul 2022 $0.14 $0.00 0.00% 4,854,269 $0.14 $0.14 $0.13

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Roger Aston Non-Executive ChairmanNon-Executive Director Jul 2015
Dr Aston is a scientist and seasoned biotechnology entrepreneur. He has been closely involved in start-up companies and major pharmaceutical companies. Aspects of his experience include US Food and Drug Administration (FDA) and European Union (EU) product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors. Dr Aston has also held Directorships/Chairmanships with Clinuvel Ltd, HalcyGen Ltd, and Ascent Pharma Ltd, was a member of the AusIndustry Biological Committee advising the Industry Research and Development Board. More recently, Dr Aston was Executive Chairman of Mayne Pharma Group from 2009 to 2011 and later, CEO of Mayne Pharma Group.
Dr Michael Stein Non-Executive Director Apr 2020
Dr Stein is currently acting CEO of immuno-oncology company, Valo Therapeutics. Immediately prior to Valo, he was the founding CEO of OxStem Ltd, an award-winning biotechnology spinout from the University of Oxford. Dr Stein previously served as founding CEO for Doctor Care Anywhere, a UK-based telemedicine platform acquired by Synergix in 2015. In 2001, he cofounded the Map of Medicine with University College London and was founding CEO. The Map was a set of clinical algorithms that represented the patient healthcare journey from suspected diagnosis to treatment across all healthcare settings. The Map was nationally licensed across NHS England and was acquired by Hearst Business Media in 2008.
Mr Brian Willoughby Leedman Executive Director Corporate Affairs May 2021
Mr Leedman is a marketing and investor relations professional with over 15 years' experience in the biotechnology industry. Mr Leedman is the founder of ResApp Diagnostics Pty Ltd which was acquired by Narhex Life Sciences Ltd to form ResApp Health. Prior to ResApp, Mr Leedman co-founded Oncosil Medical Limited and Biolife Science (QLD) Limited (acquired by Imugene Limited). Mr Leedman previously served for 10 years as Vice President, Investor Relations for pSivida Corp which is listed on the ASX and NASDAQ. He is formerly the WA chairman of AusBiotech, the association of biotechnology companies in Australia.
Mr Christopher Ntoumenopoulos Non-Executive Director Jan 2015
Mr Ntoumenopoulos is the Managing Director of Twenty 1 Corporate. He has worked in financial markets for the past 15 years, focusing on Capital Raisings, Portfolio Management and Corporate Advisory. Mr Ntoumenopoulos has advised and funded numerous ASX companies from early stage venture capital, through to IPO. He is an executive director of various private companies which span across finance, technology and medical sectors.
Dr Anthony (Tony) Keating Chief Executive OfficerManaging Director Jul 2015
Dr Keating has over ten years' experience in commercialising technology. Dr Keating created the initial business strategy for ResApp and has led the commercialization of ResApp's technology to date. Previously, Dr Keating was Director, Commercial Engagement at UniQuest Pty Ltd, one of the global leaders in commercialisation of university technology. While at UniQuest, Dr Keating held roles as interim Chief Executive Officer and Non-Executive Director for a number of privately-held, venture-capital funded start-up companies. Prior to joining UniQuest Dr Keating held business development and engineering management roles at Exa Corporation, a US-based software company that was listed on the NASDAQ and later acquired by Dassault Systemes.
Ms Nicola (Nicki) Maxine Farley Company Secretary
Nicola (Nicki) Maxine Farley Company Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 92,778,638 10.80%
Freeman Road Pty Ltd <The Avenue A/C> 35,850,000 4.17%
Sunreef Pty Ltd <Great Wall A/C> 19,749,751 2.30%
Mr Frank Weng Thong Chew 16,278,000 1.89%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <DRP A/C> 14,303,550 1.66%
Mr Anthony James Keating 10,225,000 1.19%
Hunter Capital Advisors P/L 9,000,000 1.05%
Equimetrixs Pty Ltd <The Newtonmore Superannuation Fund> 8,437,500 0.98%
Narhex Life Sciences Developments Pty Ltd 7,997,005 0.93%
CEM International (Asia) Pty Ltd 7,849,888 0.91%
Mr Yongsheng Peng & Mrs Yuezhen Xie 7,069,771 0.82%
BNP Paribas Nominees Pty Ltd <IB AU Noms Retail Client DRP> 6,254,951 0.73%
Queensland Forest Industries Pty Ltd 5,750,000 0.67%
Paranji Super Fund Pty Ltd <Paranji Superfund A/C> 5,285,000 0.62%
Citicorp Nominees Pty Limited 5,193,549 0.60%
Mr Victor John Wilk 4,400,000 0.51%
Mr Trent Antony Goodrick 4,250,000 0.49%
Mr Xiaoyi Lin 4,000,000 0.47%
Wilk Holdings Pty Ltd <Wilk Superannuation Fund A/C> 4,000,000 0.47%
Dr Geoffrey Waring 3,750,764 0.44%